The Clinical Case for Liver-First Nucleic Acid Therapeutics

Liver-targeted gene silencing is the most clinically advanced application of nucleic acid therapeutics today — not by coincidence, but because the liver’s natural propensity to take up systemically administered nanoparticles makes it the path of least resistance for intravenous LNP delivery. Two clinical data points anchor the entire field: a single dose of inclisiran (siRNA against PCSK9 mRNA) efficiently suppressed serum cholesterol for 6 months in a Phase I trial, and a single siRNA dose achieved 87% knockdown of hepatic transthyretin (TTR) in patients, with suppression lasting several weeks.

These results establish LNP-delivered siRNA as a validated clinical platform for liver targets, according to academic literature from Hannover Medical School. The high disease burden driving this work spans hepatitis B virus (HBV) infection, transthyretin amyloidosis (ATTR), dyslipidemia, and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) — conditions where the liver is both the source of pathology and the target of intervention.

The convergence of multiple therapeutic modalities on the same hepatic targets — RNAi, CRISPR/Cas9, engineered meganucleases, and AAV-based gene therapy — reflects both the commercial opportunity and the biological tractability of the liver as a therapeutic organ. According to WIPO patent filing trends, nucleic acid therapeutics represent one of the fastest-growing areas of life sciences IP activity globally, with liver indications accounting for a disproportionate share of clinical-stage programs.

RNAi Modalities: siRNA, DsiRNA, and the Expanding Target Roster

RNAi-based gene silencing via small interfering RNA (siRNA) or Dicer substrate siRNA (DsiRNA) represents the largest cluster of liver-relevant patent activity in the dataset, with filings from Alnylam Pharmaceuticals, Dicerna Pharmaceuticals (now part of Novo Nordisk), Beijing Winsunny Pharmaceutical, Silence Therapeutics, and Arrowhead Pharmaceuticals collectively covering hepatic gene targets including PNPLA3, HSD17B13, DGAT2, ALAS1, LPA, LDHA, and HBV. The mechanism involves sequence-complementary binding of the antisense strand to target mRNA, loading into the RISC complex, and RISC-mediated cleavage.

Chemical modifications — including 2′-O-methyl, 2′-F, and phosphorothioate internucleotide linkages — are employed across these filings to improve nuclease stability and reduce immunostimulation. These modifications are now standard in clinical-grade siRNA constructs. Research published by Nature and affiliated journals has documented the pharmacokinetic advantages conferred by such chemical scaffolds in systemic delivery contexts.

The NAFLD/NASH target space is particularly crowded. Alnylam Pharmaceuticals and Amgen both hold active or pending patent families on RNAi against PNPLA3, while Beijing Winsunny Pharmaceutical has filed pending patents on siRNA conjugates for both HSD17B13 and DGAT2. Amgen’s filing goes further, specifically claiming preferential inhibition of the PNPLA3-rs738409 risk allele over the reference allele — an allele-selective approach designed to maximize therapeutic index for genetically at-risk patients.

Beyond metabolic disease, Alnylam’s dsRNA compositions targeting ALAS1 address acute hepatic porphyria — a disease area distinct from metabolic or infectious liver disease. Dicerna’s LNP-formulated DsiRNA targeting LDHA is described as well-tolerated in vivo and positioned for primary hyperoxaluria type 1 (PH1) as well as oncology applications. For LPA (apolipoprotein(a)), both Dicerna Pharmaceuticals and Silence Therapeutics hold active Japanese patents describing RNAi oligonucleotides inhibiting LPA expression, with Silence Therapeutics disclosing a serinol-derived linker for 3’/5′ ligand attachment to enable in vivo hepatocyte targeting.

“87% knockdown of hepatic transthyretin in patients following a single siRNA dose, lasting several weeks — clinical evidence for LNP-mediated siRNA efficacy in the liver.”

CRISPR/Cas9 and Epigenetic Editing via LNP: From Bench to Clinic

CRISPR-based approaches to liver gene silencing have reached the clinic through Intellia Therapeutics’ LNP-formulated Cas9 mRNA and TTR-targeting guide RNA, representing the first systemic administration of a CRISPR/Cas9-based therapeutic for in vivo editing in a clinical trial. The therapeutic threshold is defined as greater than 60–80% reduction in serum prealbumin, with systemic IV administration as the delivery route. This is the most direct clinical evidence in the patent dataset and marks a significant milestone for the broader gene editing field as tracked by organizations including the FDA.

Harvard University (President and Fellows of Harvard College) has also filed a patent on CRISPR-Cas systems specifically for liver targeting and treatment, reinforcing the academic foundation underpinning commercial CRISPR-liver programs. The overlap between academic IP and commercial development is a characteristic feature of this space, with freedom-to-operate assessments requiring attention to both university-held foundational patents and company-specific delivery and sequence claims.

A distinct and more recent direction involves epigenetic silencing rather than permanent DNA cuts. Tune Therapeutics’ 2025 pending patent describes a multiplexed CRISPR-Cas epigenetic repression system targeting two or more LDL-regulating genes simultaneously — including PCSK9 — using transcriptional repressors rather than nucleases. This approach targets familial hypercholesterolemia and signals a shift toward durable transcriptional silencing that may carry a more favorable safety profile than permanent genome editing. Epigenetic CRISPR approaches remain at the preclinical stage based on available data in the dataset.

Precision BioSciences has filed multiple Chinese patent applications describing optimized engineered meganucleases that recognize and cleave sequences within the HBV genome across multiple genotypes. The suicide gene insertion strategy — where homologous recombination is used to knock in a gene that kills HBV-infected cells — is disclosed. This modality combines nuclease delivery with targeted cytotoxicity, but retrieved data is patent-only with no clinical signal evident.

The Delivery Landscape: LNPs, Conjugates, AAV, and Beyond

Lipid nanoparticles containing ionizable cationic lipids are the most advanced delivery platform for systemic administration of RNAi therapeutics, as confirmed by academic literature in the dataset, with liver tropism as the predominant outcome of systemic LNP administration. Acuitas Therapeutics has filed a foundational patent describing LNPs containing cationic lipids for delivery of mRNAs encoding engineered nucleases or guide RNAs, explicitly naming hepatic safe harbor loci — the albumin gene and AAVS1 — as genomic targets.

However, LNP dependence is not universal in the patent landscape. Multiple recent (2023–2025) filings from Chinese pharmaceutical companies describe siRNA conjugates and prodrug formats for hepatocyte-specific delivery without LNP encapsulation. Beijing Winsunny Pharmaceutical and Suzhou Ribo Biotechnology each describe such approaches, likely utilizing GalNAc or equivalent targeting moieties for receptor-mediated hepatocyte uptake. This strategy — enabling potential subcutaneous administration as an alternative to IV LNP infusion — signals commercial interest in simplified delivery platforms. The EMA has previously recognized GalNAc conjugation as a validated hepatocyte targeting mechanism in its assessment of approved RNAi products.

UniQure IP B.V. has filed two active patent families covering synthetic liver-specific viral promoters designed to drive transgene expression in hepatocytes with minimal activity in non-hepatic cells such as A549 lung cells. These promoters are intended for AAV gene therapy vectors and achieve at least 2–50x higher liver-specific expression than the LP1 promoter benchmark. This represents a cell-type specificity strategy that complements — rather than competes with — LNP and conjugate delivery platforms.

A 2024 filing from Renjing (Suzhou) Biotechnology describes poly(A) tail engineering with miRNA binding sites to reduce mRNA expression in non-hepatocyte liver cells — including liver sinusoidal endothelial cells and hepatic stellate cells — while preserving hepatocyte expression. This cell-type resolution strategy within the liver itself represents a further refinement of specificity beyond organ-level targeting.

Competitive IP Signals and Emerging Strategic Directions

LNP-delivered siRNA and CRISPR are converging on the same hepatic targets: Alnylam (siRNA), Intellia (CRISPR/LNP), and Tune Therapeutics (epigenetic CRISPR/LNP) all address PCSK9 and metabolic liver disease. This creates overlapping modality claims that require careful freedom-to-operate analysis. The patent landscape as documented by the EPO and USPTO reflects a field where foundational delivery IP (Acuitas LNP compositions, Harvard CRISPR-Cas systems) intersects with target-specific sequence claims from therapeutic developers.

Several strategic implications emerge from the dataset. First, conjugate-based delivery without LNP is an emerging commercial differentiator: multiple recent (2023–2025) patent filings from Chinese pharmaceutical companies describe siRNA conjugates and prodrugs for liver targets, signaling intensifying Chinese generics and biologics entry into the RNAi therapeutic space with implications for both IP competition and market access in Asian markets.

Second, PNPLA3, HSD17B13, and DGAT2 are consolidating as the NAFLD/NASH RNAi target triad. Three distinct assignees — Alnylam, Amgen, and Beijing Winsunny — hold pending or active IP on RNAi against these three genes. Academic and clinical development for these targets remains at early stages in the retrieved data, but IP filing density suggests anticipated pivotal trial activity.

Third — and perhaps most strategically significant — the retrieved academic literature explicitly notes that “siRNA delivery beyond the liver is not yet feasible in the clinic.” This constraint means liver-targeted programs are currently the primary commercially viable RNAi application, making this therapeutic area disproportionately important for near-term RNAi revenue. It also creates a clear white space for non-LNP, non-hepatic delivery platforms — a gap that multiple academic and commercial groups are actively working to close.

The co-existence of Arrowhead Pharmaceuticals (RNAi triggers with in vivo primate safety data showing blood urea nitrogen, creatinine, AST, and ALT safety profiles) and Precision BioSciences (meganucleases with suicide gene knock-in) targeting HBV suggests an emerging combination landscape where RNAi suppresses viral replication acutely while genome editing or meganuclease-suicide strategies pursue viral DNA elimination — a potential path to functional cure for chronic HBV.

“SiRNA delivery beyond the liver is not yet feasible in the clinic — making liver-targeted programs disproportionately important for near-term RNAi revenue.”

Mina Therapeutics Limited has filed a patent on short activating RNA (saRNA) that upregulates albumin production by activating CEBPA, HNF4a, or albumin itself, for treating liver cirrhosis, hepatitis, and hypoalbuminemia. This gene activation strategy — rather than silencing — represents a distinct therapeutic direction within the hepatocyte-targeted nucleic acid space, though development stage is not explicitly stated in the retrieved patent data.